Tuesday, Addex Therapeutics Ltd (NASDAQ:ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume of 4.16K as per data from Benzinga Pro.
Addex Therapeutics and Indivior PLC (NASDAQ:INDV) announced that they have selected clinical candidates from their GABAB-positive allosteric modulator (PAM) research collaboration.
Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of their selected compound.
Under the terms of the agreement, Addex is eligible for payment of up to $330 million on achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit.
Under the terms of the agreement, Addex has also exercised its right to select a compound to advance its own independent GABAB PAM program for chronic cough.
"Indivior's collaboration with Addex has been instrumental in identifying a possible candidate for the treatment of substance use disorders," said Christian Heidbreder, Chief Scientific Officer at Indivior."
"The selection of GABAB PAM clinical candidates is the culmination of more than five years of research at Addex in close collaboration with the team at Indivior...We look forward to the next steps in the development of the substance use disorder program under the control of Indivior," said Tim Dyer, CEO of Addex. "On the Addex side, we are now focused on advancing our selected clinical candidate for chronic cough into IND-enabling studies."
In July, Addex Therapeutics announced that its partner Janssen Pharmaceuticals, Inc., a unit of Johnson & Johnson (NYSE:JNJ), discontinued the development of ADX71149 (JNJ-40411813) in epilepsy.
The decision follows top-line Phase 2 data announced in April, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
Price Action: ADXN stock is 63.2% at $12.50 during the premarket session at last check Tuesday.
星期二，Addex Therapeutics股票(NASDAQ:ADXN)的交易量較平均交易量0.416萬高，達到379萬，據Benzinga Pro數據。
Addex Therapeutics和Indivior PLC(NASDAQ:INDV)宣佈，他們已從他們的GABAb陽性變構調節劑(PAM)研究合作中選出了臨床候選藥物。
Indivior已爲將來的物質使用障礙開發選擇了一種化合物，並將對其選擇的化合物進行一切未來的開發工作。
根據協議條款，Addex有資格獲得最高3.3億元的預先指定的法規、臨床和商業里程碑上的支付，以及根據淨銷售額的層級獲得分層版稅，從高個位數到低兩位數。
根據協議的條款，Addex還行使了自己選擇一個化合物來推進自己獨立的GABAb PAm慢性咳嗽項目的權利。
「Indivior與Addex的合作在發現可能用於物質使用障礙治療的候選藥物方面起到了關鍵作用，」Indivior首席科學官Christian Heidbreder說。
「在與Indivior團隊進行了五年多的密切合作後，GABAb PAm臨床候選藥物的選擇是Addex研究的頂點...我們期待着根據Indivior的控制下推動物質使用障礙項目的下一步，」Addex首席執行官Tim Dyer表示。「在Addex方面，我們現在專注於推進我們選擇的慢性咳嗽臨床候選藥物進入IND準備研究。」
七月，Addex Therapeutics宣佈，其合作伙伴強生製藥公司 (Johnson & Johnson旗下單位，紐交所:JNJ)在癲癇治療中終止了ADX71149 (JNJ-40411813)的開發。
該決定是基於4月份宣佈的2期臨床試驗的初步數據，該數據顯示，在具有局竈性發作癲癇並對左乙拉西坦或布利脲酯反應不良的患者中，輔助使用ADX71149（JNJ-40411813）與標準治療相比，無法達到統計學意義上的主要終點，即患者達到基線癲癇發作次數所需時間。
價格走勢：截至週二最後一次查詢，ADXN股票在盤前交易中上漲63.2%，報12.50美元。
